(STE) STERIS - NYSE
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 19.746m USD | Total Return: -11.5% in 12m
Avg Turnover: 174M
EPS Trend: 98.6%
Qual. Beats: 0
Rev. Trend: 89.1%
Qual. Beats: 0
Warnings
Fakeout
Tailwinds
No distinct edge detected
STERIS plc (NYSE: STE) is a global provider of infection prevention products and services, organized into three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. Its offerings span cleaning chemistries, sterility assurance products, endoscope reprocessors and accessories, sterilizers, washers, surgical tables and lights, and instrument repair and maintenance services, as well as outsourced sterile processing for hospitals and contract sterilization, process validation, and equipment support for medical device and pharmaceutical manufacturers. The company is headquartered in Mentor, Ohio, and serves healthcare providers, medical device and pharmaceutical manufacturers, and biopharmaceutical facilities across the United States, Ireland, and other international markets. Founded in 1985 and listed on the NYSE in 1992, STERIS sits within the Health Care Equipment sub-industry and benefits from a business model that combines capital equipment sales with recurring service revenue from maintenance contracts and industrial-scale contract sterilization, a mission-critical step in the production of single-use medical devices.
- Hospital procedure volumes drive Healthcare consumables and services revenue
- Medical device sterilization demand lifts Applied Sterilization Technologies margins
- Biopharma capex recovery supports Life Sciences segment revenue growth
| Net Income: 782.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.39 > 1.0 |
| NWC/Revenue: 21.05% < 20% (prev 17.92%; Δ 3.13% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.34b > Net Income 782.4m |
| Net Debt (1.80b) to EBITDA (1.83b): 0.99 < 3 |
| Current Ratio: 2.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (98.4m) vs 12m ago -0.36% < -2% |
| Gross Margin: 44.25% > 18% (prev 44.01%; Δ 0.24% > 0.5%) |
| Asset Turnover: 56.85% > 50% (prev 53.81%; Δ 3.04% > 0%) |
| Interest Coverage Ratio: 18.20 > 6 (EBIT TTM 1.10b / Interest Expense TTM 60.7m) |
| A: 0.12 (Total Current Assets 2.39b - Total Current Liabilities 1.15b) / Total Assets 10.7b |
| B: 0.28 (Retained Earnings 3.02b / Total Assets 10.7b) |
| C: 0.11 (EBIT TTM 1.10b / Avg Total Assets 10.4b) |
| D: 2.03 (Book Value of Equity 7.18b / Total Liabilities 3.54b) |
| Altman-Z'' = 4.52 = AA |
| DSRI: 0.96 (Receivables 1.09b/1.04b, Revenue 5.94b/5.46b) |
| GMI: 0.99 (GM 44.01% / 44.25%) |
| AQI: 0.94 (AQ_t 0.56 / AQ_t-1 0.59) |
| SGI: 1.09 (Revenue 5.94b / 5.46b) |
| TATA: -0.05 (NI 782.4m - CFO 1.34b) / TA 10.7b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of June 26, 2026, the stock is trading at USD 210.60 with a total of 652,601 shares traded. Over the past week, the price has changed by +5.62%, over one month by -2.33%, over three months by -5.44% and over the past year by -11.45%.
Current recommended Stop Loss: 203.70 (which is 3.3% or 1.4 ATR below the current price).
STERIS has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold STE.
- StrongBuy: 3
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 256.9 | 22% |
P/E Trailing = 25.5821
P/E Forward = 18.1818
P/S = 3.3265
P/B = 2.7487
P/EG = 1.6385
Revenue TTM = 5.94b USD
EBIT TTM = 1.10b USD
EBITDA TTM = 1.83b USD
Long Term Debt = 1.81b USD (from longTermDebt, last quarter)
Short Term Debt = 154.7m USD (from shortTermDebt, last quarter)
Debt = 2.24b USD (from shortLongTermDebtTotal, last quarter) + Leases 155.4m
Net Debt = 1.80b USD (calculated: Debt 2.24b - CCE 439.6m)
Enterprise Value = 21.5b USD (19.7b + Debt 2.24b - CCE 439.6m)
Interest Coverage Ratio = 18.20 (Ebit TTM 1.10b / Interest Expense TTM 60.7m)
EV/FCF = 22.16x (Enterprise Value 21.5b / FCF TTM 972.4m)
FCF Yield = 4.51% (FCF TTM 972.4m / Enterprise Value 21.5b)
FCF Margin = 16.38% (FCF TTM 972.4m / Revenue TTM 5.94b)
Net Margin = 13.18% (Net Income TTM 782.4m / Revenue TTM 5.94b)
Gross Margin = 44.25% ((Revenue TTM 5.94b - Cost of Revenue TTM 3.31b) / Revenue TTM)
Gross Margin QoQ = 43.89% (prev 43.81%)
Tobins Q-Ratio = 2.01 (Enterprise Value 21.5b / Total Assets 10.7b)
Interest Expense / Debt = 2.71% (Interest Expense 60.7m / Debt 2.24b)
Taxrate = 25.04% (262.2m / 1.05b)
NOPAT = 828.1m (EBIT 1.10b * (1 - 25.04%))
Current Ratio = 2.09 (Total Current Assets 2.39b / Total Current Liabilities 1.15b)
Debt / Equity = 0.31 (Debt 2.24b / totalStockholderEquity, last quarter 7.18b)
Debt / EBITDA = 0.99 (Net Debt 1.80b / EBITDA 1.83b)
Debt / FCF = 1.85 (Net Debt 1.80b / FCF TTM 972.4m)
Total Stockholder Equity = 7.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.49% (Net Income 782.4m / Total Assets 10.7b)
RoE = 11.05% (Net Income TTM 782.4m / Total Stockholder Equity 7.08b)
RoCE = 12.42% (EBIT 1.10b / Capital Employed (Equity 7.08b + L.T.Debt 1.81b))
RoIC = 8.76% (NOPAT 828.1m / Invested Capital 9.45b)
WACC = 6.51% (E(19.7b)/V(22.0b) * Re(7.02%) + D(2.24b)/V(22.0b) * Rd(2.71%) * (1-Tc(0.25)))
Discount Rate = 7.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.41 | Cagr: -0.43%
[DCF] Terminal Value 77.97% ; FCFF base≈894.6m ; Y1≈1.03b ; Y5≈1.51b
[DCF] Fair Price = 214.6 (EV 22.7b - Net Debt 1.80b = Equity 20.9b / Shares 97.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.61 | EPS CAGR: 7.74% | SUE: -0.31 | # QB: 0
Revenue Correlation: 89.06 | Revenue CAGR: 7.34% | SUE: -0.04 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.50 | Chg30d=+0.38% | Revisions=+0% | Analysts=7
EPS next Quarter (2026-09-30): EPS=2.70 | Chg30d=+0.12% | Revisions=+11% | Analysts=7
EPS current Year (2027-03-31): EPS=11.16 | Chg30d=+0.08% | Revisions=+0% | GrowthEPS=+9.7% | GrowthRev=+7.3%
EPS next Year (2028-03-31): EPS=12.18 | Chg30d=+0.66% | Revisions=-25% | GrowthEPS=+9.2% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: -25%